CATEGORY

Analytical Testing Services

Labs that evaluate varyig dose formulation of a given API.

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Analytical Testing Services.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo

Analytical Testing Services Market Monitoring Dashboard


Supply Demand

Understand the correlation between costs, margins, and prices impacting your category on a real time basis on Beroe LiVE.Ai™

Analytical Testing Services Industry Benchmarks


Savings Achieved

(in %)

The average annual savings achieved in Analytical Testing Services category is 1.60%

Payment Terms

(in days)

The industry average payment terms in Analytical Testing Services category for the current quarter is 90.0 days

Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™

Category Strategy and Flexibility

Engagement Model

Supply Assurance

Sourcing Process

Supplier Type

Pricing Model

Contract Length

SLAs/KPIs

Lead Time

Supplier Diversity

Targeted Savings

Risk Mitigation

Financial Risk

Sanctions

AMEs

Geopolitical Risk

Cost Optimization

Price per Unit Competitiveness

Specification Leanness

Minimum Order Quality

Payment Terms

Inventory Control

Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Analytical Testing Services Suppliers


    18,804
    Total Suppliers
    1,478
    Diverse Suppliers
    84
    Normalized Supplier Rating
    Analytical Testing Services Supplier

    Find the right-fit analytical testing services supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance
    36

    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77

    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Analytical Testing Services market report transcript


    Global Market Size and Growth Forecast –Analytical Testing Services industry

    • The global demand for analytical testing services is expected to grow at approx. 11–12 percent CAGR through 2020–2025
    • Pharmaceutical companies are outsourcing manufacturing and development services, due to the nature of business being capital intensive, growing demand of biologics and generic medicines
    • North America is the preferred region, followed by Asia Pacific, mainly due to the low cost of operations and continuous evolving nature of regulation

    Global Outsourcing Market Trend

    • PDS outsourcing spend is expected to increase from $3.15 billion to $4.1 billion in 2018
    • Outsourcing budgets have increased in recent years, swinging from contractions to expansion after the 2008 recession
    • Pharma is maintaining its stance on outsourcing as a cost savings strategy
    • Demands for biologics is a boon for contract manufacturing and contract research organizations

    Growth Drivers and Constraints

    Drivers

    Increased investment in R&D

    • Increased investments at the discovery and early development phases are leading to robust pipelines and creating demand for greater clinical--scale manufacturing capacity.

    Increase in biologic drugs

    • The percentage of expenditure going towards biologics development and outsourcing expenditure have both risen over last year.

    Broad array of services offering

    • CDMOs are increasingly motivated to offer an expanded array of enhanced drug-delivery technologies, giving their customers broader options for patient care. Delivery technologies can include various targeted and timed release/dissolution and formulation technologies.

    Increase in drug molecule complexity

    • Drug molecules are becoming more complex and increasingly require both advanced synthesis and formulation expertise to realize cost-effective, efficacious medicines

    Constraints

    Pressure of cost reductions

    • The pressure on pharmaceutical firms to reduce costs was transferred to suppliers, which translated into reduced profit margins for suppliers.

    Decline in number of initial public offerings (IPO)

    • Without public markets, the industry could see a sharp drop in IND filings, and in the demand for CDMO services, as it did in 2010.

    Increasing pharmaceutical In-house capability

    • The pharma-biotech are investing significantly in internal manufacturing capabilities, through the expansion of existing or additional new manufacturing facilities and/or the acquisition of production capability